The vaccine was 100 per cent effective when it was tested on more than 4,000 people who were in close contact with Ebola patients in the African nation of Guinea, the World Health Organization (WHO) said, citing a study published today in the Lancet medical journal. The trial of the vaccine, called Ebola ca suffit-"Ebola, that's enough" in French - began on March 23.
Ebola has killed more than 11,000 people in West Africa following an outbrea k at the end of 2013. While the incidence has fallen off sharply, it hasn't been eradicated, with seven confirmed cases in the week of July 29. The drug from Merck is one of several vaccines in clinical trials, with GlaxoSmithKline Plc and Novavax Inc also developing medicines.
"This is an extremely promising development," Margaret Chan, director-general of the WHO, stated. "An effective vaccine will be another very important tool for both current and future Ebola outbreaks."
The vaccine was developed by the Public Health Agency of Canada and licensed to NewLink Genetics Corp. In November, Merck entered in an agreement to research, develop and distribute the drug.
NewLink shares surged 7.6 per cent to $55.04 in early trading, while Merck rose 1.9 per cent to $59.60. Kenilworth, New Jersey-based Merck gets more than 10 per cent of its $40 billion in annual revenue from sales of vaccines for illnesses such as human papillomavirus, or HPV, and shingles.
In the study, people were protected against the Ebola virus within six to 10 days of vaccination.
The late-stage trial is continuing, and other studies are in progress, with the goal of submitting the vaccine for regulatory approval around the world.
To create the vaccine, scientists removed a gene from another virus, vesicular stomatitis, and replaced it with an Ebola virus gene that can't cause the disease alone. That could let people who get the vaccine develop antibodies against Ebola.
It's still unclear how significant or long the immune response to the vaccine will be, Merck said.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories
Over 30 subscriber-only stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app